2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Pocket Pal
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Eric S. Rosenthal, MD (he/him/his)

Massachusetts General Hospital, Massachusetts

Eric S. Rosenthal, MD, is a clinician-scientist and national leader in clinical artificial intelligence, with a focus on building the data, governance, and translational infrastructure needed for collaborative and trustworthy AI in medicine. Board certified in Neurology, Neurocritical Care, and Epilepsy, he directs the Neuroscience Intensive Care Unit at Massachusetts General Hospital and serves as Program Director of the Mass General Brigham NeuroAI Center.

Dr. Rosenthal’s work centers on developing and validating digital health biomarkers of neurologic injury, recovery, and treatment response, and on deploying these tools in multicenter clinical trials and implementation science. He is the Contact Principal Investigator of the NIH Bridge2AI CHoRUS for Clinical Care AI program, where he leads an interdisciplinary consortium spanning 19 hospitals to implement interoperable data standards and assemble one of the nation’s largest high-resolution multimodal datasets for clinical AI, integrating electronic health record, waveform, and imaging data. Building on this effort, he also co-developed a national AI workforce training initiative through the NIH AIM-AHEAD Bridge2AI Training Program.

Nationally, Dr. Rosenthal serves as Co-Chair of the NIH Bridge2AI Consortium Steering Committee, helping lead a network of more than 400 members advancing AI infrastructure, standards, best practices, and model development across flagship datasets. Within Massachusetts, he serves on the Massachusetts AI Hub Governance Workgroup.

A central theme of his research is improving care for patients with life-threatening neurologic illness. He has developed and validated quantitative brain-monitoring biomarkers in traumatic brain injury, refractory seizures and status epilepticus, and hemorrhagic stroke. He currently serves as Co-Principal Investigator of the Ketamine for Established Status Epilepticus Treatment Trial, or KESETT, and the ELECTRO-BOOST traumatic brain injury study, both of which aim to establish scalable quantitative measures of brain recovery and treatment response in large multicenter trials of emerging therapies.

Presentation(s):